Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $67.50 at Chardan Capital

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective lifted by Chardan Capital from $60.00 to $67.50 in a report released on Monday morning, The Fly reports. They currently have a buy rating on the stock.

Several other analysts have also issued reports on TSHA. Zacks Investment Research lowered shares of Taysha Gene Therapies from a hold rating to a sell rating in a research report on Tuesday, March 9th. William Blair initiated coverage on shares of Taysha Gene Therapies in a research note on Monday, March 1st. They set an outperform rating and a $46.00 price objective for the company. Oppenheimer initiated coverage on shares of Taysha Gene Therapies in a research note on Monday, January 4th. They set an outperform rating and a $42.00 price objective for the company. Finally, Morgan Stanley boosted their price objective on shares of Taysha Gene Therapies from $29.00 to $30.00 and gave the company an overweight rating in a research note on Monday, March 15th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $43.92.

NASDAQ TSHA opened at $25.57 on Monday. The company has a 50 day simple moving average of $23.84. Taysha Gene Therapies has a 12-month low of $18.16 and a 12-month high of $33.35.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, March 2nd. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.68). On average, sell-side analysts expect that Taysha Gene Therapies will post -3.19 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. Citigroup Inc. purchased a new position in Taysha Gene Therapies in the 4th quarter worth approximately $43,000. Strs Ohio purchased a new position in Taysha Gene Therapies in the 4th quarter worth approximately $55,000. New York State Common Retirement Fund purchased a new position in Taysha Gene Therapies in the 4th quarter worth approximately $130,000. Point72 Hong Kong Ltd purchased a new position in Taysha Gene Therapies in the 3rd quarter worth approximately $132,000. Finally, American International Group Inc. purchased a new position in Taysha Gene Therapies in the 4th quarter worth approximately $134,000. 42.19% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome.

See Also: How Do Mutual Funds Work?

The Fly

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.